TMR releases updated report on meningococcal vaccines market
TMR said the report analyzes the market depending on its market segments, current trends and major geographies. The meningococcal vaccine market is segmented on the basis of types of vaccines available, including a quadrivalent vaccine which protects against four of six meningococcal disease serotypes, a bivalent vaccine and three individual vaccines.
The company said the report represents a complete study of current market trends, industry growth drivers and restraints. The report includes detailed profiles of the top industry players in the market, including Baxter International, Inc., Pfizer, GlaxoSmithKline, Novartis and Sanofi Pasteur.
Meningococcal polysaccharide vaccine and meningococcal conjugate vaccine are two types of quadrivalent vaccines against Nisseria meningitides, a bacterium that causes meningococcal diseases. While meningococcal polysaccharide vaccines like Sanofi's Menomune represent the only meningococcal vaccines available in the U.S. for people older than 55 years of age, quadrivalent conjugate vaccines account for the largest share of global sales. Meningococcal conjugate vaccines like Sanofi's Menactra and Novartis' Menveo are usually preferred for individuals 55 years of age and younger.
There are six serotypes of meningococcal disease, serogroups A, B, C, Y, W 135 and X, that are responsible for most cases of meningococcal disease among humans. According to the World Health Organization, Africa has been affected by serogroup A meningococcal diseases every seven to 14 years for the last 100 years, particularly in the African meningitis belt. MenAfriVac is a serogroup A vaccine that is used extensively in Africa to eliminate the disease.
TMR's report includes Porter's five force model analysis, market projections for the coming years, detailed value chain analysis and a review of micro and macro factors essential for new entrants to the market as well as for existing market players.